In combination with chemo-, radio- or immunotherapy FAK inhibitors are now emerging as valuable anti-tumor agents by blocking FAK and/or PYK2 from providing survival mechanisms under stress conditions, such as DNA damage or immunological stress. Here, PTK2B is linked to neoplasm.